This is a renewal application for years 33-37 of GM07171 which supports the Medical Scientist Training Program (MSTP) at Duke University. One of the first MSTP's, this Program has been continually funded by the National Institutes of General Medical Sciences, the first ten years as GM01678 (1966-1975) and the subsequent 29 years as GM07171 (1975-2004). The Program currently has an award of 36 funded positions and is requesting the same number of slots in this renewal. However, the Program has grown significantly since the previous application in 1996 when there were 42 students. Currently, there are 73 students and the Program is now at a new steady state of 70-84 students. This number represents 10 to12% of the Medical School class. The additional funding is provided by the Medical and Graduate Schools, the Duke Medical Alumni Association, and the Duke Endowment. In addition, a $1,000,000 reserve fund has been created to cover unexpected financial needs by the Program. The current Program student body is quite diverse with 19% underrepresented minority enrollment and a gender distribution that is 45% female. A large pool of applicants (200-300 per year) has allowed us to recruit an outstanding group of students. The structure of the Program is unchanged since the prior application. It consists of a basic science core year, a clinical core year, graduate school, and return to a final clinical year. The average program length is 7.4 years. Students may spend their graduate years in the traditional Medical School basic sciences, Chemistry, Zoology, and Biomedical Engineering. Greater flexibility is now available to our students who may also opt a new Biostatistics and Bioinformatics Department, Economics, or Cognitive Neuroscience/Psychology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
3T32GM007171-36S2
Application #
8106579
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Hagan, Ann A
Project Start
1975-07-01
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
36
Fiscal Year
2010
Total Cost
$48,734
Indirect Cost
Name
Duke University
Department
Pathology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Suryadevara, Carter M; Desai, Rupen; Abel, Melissa L et al. (2018) Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology 7:e1434464
Toomey, Christopher B; Landowski, Michael; Klingeborn, Mikael et al. (2018) Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 59:662-673
Reap, Elizabeth A; Suryadevara, Carter M; Batich, Kristen A et al. (2018) Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res 78:256-264
Detter, Matthew R; Snellings, Daniel A; Marchuk, Douglas A (2018) Cerebral Cavernous Malformations Develop Through Clonal Expansion of Mutant Endothelial Cells. Circ Res 123:1143-1151
Cocce, Kimberly J; Stinnett, Sandra S; Luhmann, Ulrich F O et al. (2018) Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints. Am J Ophthalmol 189:127-138
Smith, Jeffrey S; Lefkowitz, Robert J; Rajagopal, Sudarshan (2018) Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov 17:243-260
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Toomey, Christopher B; Johnson, Lincoln V; Bowes Rickman, Catherine (2018) Complement factor H in AMD: Bridging genetic associations and pathobiology. Prog Retin Eye Res 62:38-57
Gedeon, Patrick C; Schaller, Teilo H; Chitneni, Satish K et al. (2018) A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clin Cancer Res 24:3611-3631
Xu, MengMeng; Seas, Andreas; Kiyani, Musa et al. (2018) A temporal examination of calcium signaling in cancer- from tumorigenesis, to immune evasion, and metastasis. Cell Biosci 8:25

Showing the most recent 10 out of 346 publications